Dr. van den Bent on Next Steps for ABT-414 in Brain Cancer
November 18th 2016Martin J. van den Bent, MD, ‎Head Neuro-Oncology Unit at Erasmus MC Cancer Center, discusses what the next trials will be for ABT-414, anti-EGFR antibody-drug conjugate under exploration for patients with brain cancer.
Read More